Fresh analysis reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise programs.
Published data in a prominent health publication shows that while overweight individuals often shed a large proportion of their body weight while on the medication, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing these drugs must be informed of the potential of fast rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment weight within about 18 months.
Comparing Approaches
The research, which looked at 37 of trials involving thousands of participants, contrasted the results of the injectable medications with other pills.
Researchers point out that individuals who lose weight through dieting generally experience a slower creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Fast Regain
Doctors suggest the mode of action of the injections is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to produce less of its endogenous hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the therapy is often life-long.
This view is echoed by drug manufacturers, who note that the results "emphasize the long-term character of obesity," similar to managing conditions like diabetes.
User Testimonies
Individuals who have stopped the medication report a intense resurgence of appetite.
"It felt as if a trigger that goes on and I was suddenly extremely hungry," described an individual.
This challenge is worsened if users have not adopted permanent dietary or behavioural changes during treatment.
Significant Adoption
Figures suggest that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Use is higher among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while the jabs are powerful agents for shedding pounds, they are not a standalone fix and long-term success relies on combined behavioural management.
